ライフサイエンスコーパス: myelopathy

1 multiplex, 4 myopathy, 3 motor neuropathy, 2 myelopathy).

2 ompression surgery for degenerative cervical myelopathy.

3 ith moderate-to-severe degenerative cervical myelopathy.

4 NMDCCC), i.e., without clinically manifested myelopathy.

5 opical spastic paraparesis/HTLV-I-associated myelopathy.

6 sc herniation can result in acute or chronic myelopathy.

7 + T cells in patients with HTLV-I-associated myelopathy.

8 adult T-cell leukemia and HTLV-1-associated myelopathy.

9 ine, after development of objective signs of myelopathy.

10 opical spastic paraparesis/HTLV-I-associated myelopathy.

11 owed focal radiological evidence of cervical myelopathy.

12 ated with adult T-cell leukemia/lymphoma and myelopathy.

13 to cervical spine instability and subsequent myelopathy.

14 rm paraesthesia, dysphagia, and worsening of myelopathy.

15 e, of whom none had hearing loss, ataxia, or myelopathy.

16 copper deficiency usually co-occurring with myelopathy.

17 here were no localizing signs or evidence of myelopathy.

18 adiological, and neurophysiological signs of myelopathy.

19 uggests that spondylosis is the cause of the myelopathy.

20 r NMO-IgG may lead to an alternate cause for myelopathy.

21 nal damage in a reversible phase of cervical myelopathy.

22 hic lateral sclerosis, and radiation-induced myelopathy.

23 ll leukemia and tropical spastic paraparesis/myelopathy.

24 the etiopathogenesis of canine degenerative myelopathy.

25 opical spastic paraparesis/HTLV-1-associated myelopathy.

26 T lymphocytes that may lead to leukemia and myelopathy.

27 tion; some had acute monophasic or relapsing myelopathy.

28 myelitis, and unspecified neurodegenerative myelopathy.

29 l therapies for the treatment of devastating myelopathies.

30 riteria for BD; (2) clinically suggestive of myelopathy; (3) simultaneous spinal cord and brain magne

31 han other causes of longitudinally extensive myelopathy (50/156 (32%) vs 0/66 (0%); p</=0.001) but di

32 In addition, cluster 1 had a higher rate of myelopathy (67%, n = 6 vs. 18%, n = 2; P = 0.028).

33 The incidence of preexisting myelopathy (69%) and the extent of decompression (2.38 l

34 ials demonstrated central slowing supporting myelopathy (96%).

35 Fewer patients with cervical myelopathy achieved the PCS MCID (59%).

36 ical spine stenosis and symptomatic cervical myelopathy after decompressive surgery using (18)F-FDG P

37 Recently, reports of acute myelopathy after the administration of CAR T-cell therap

38 ith moderate-to-severe degenerative cervical myelopathy aged 18-80 years, who had a modified Japanese

39 deficits associated with encephalopathy and myelopathy also occur.

40 eurodegenerative disorder, HTLV-I associated myelopathy (also known as tropical spastic paraparesis),

41 T-cell leukemia (ATL) and HTLV-1 associated myelopathy, also called tropical spastic paraparesis (HA

42 number of inflammatory conditions, including myelopathy, although the majority of individuals who are

43 opical spastic paraparesis/HTLV-1-associated myelopathy, among other disorders.

44 tropical spastic paraparesis-HTLV-associated myelopathy and ATLL or healthy carriers may be relevant

45 FA is a biomarker for the severity of myelopathy and for subsequent surgical outcome.

46 apsin response-mediator protein-5 autoimmune myelopathy and occult neoplasia are important considerat

47 The clinical severity of myelopathy and postoperative recovery were assessed by u

48 One exhibited a myelopathy and the other chronic endocrine problems (Sch

49 Twenty people with cervical myelopathy and twenty healthy controls, were studied.

50 Subjects with more severe myelopathy and with high DR expression on CD8+ lymphocyt

51 ly diagnosed with neoplastic or inflammatory myelopathies, and decompressive surgery was delayed by a

52 Cognitive disorders, vacuolar myelopathy, and sensory neuropathies associated with HIV

53 arthrosis of non-spinal joints, worsening of myelopathy, and wound complications.

54 vical disc dislocation, vertebral fractures, myelopathy, and/or cancer.

55 (MRIs) within 1 month of acute worsening of myelopathy; and (4) follow-up duration >/= 1 year after

56 Several autoimmune myelopathies are recognized clinically.

57 T-cell lymphotropic virus (HTLV)-associated myelopathy are described.

58 clinical and distinctive imaging features of myelopathy associated with Behcet's disease (BD).

59 ensorimotor neuropathies, cerebellar ataxia, myelopathy, brain stem and limbic encephalopathy.

60 rom other causes of longitudinally extensive myelopathies but not from MS.

61 ed with an increased risk of HTLV-associated myelopathy, but little is known about variation in HTLV-

62 istinguished from other disorders that cause myelopathy by results from laboratory and radiological i

63 onic neurological symptoms due to congestive myelopathy caused by intradural spinal AVMs.

64 ically and radiologically at our specialised myelopathy clinic.

65 to predict neurological recovery in cervical myelopathy (CM) based on clinical images of the cervical

66 cortex of patients with cervical spondylotic myelopathy (CSM) by using proton magnetic resonance (MR)

67 Cervical spondylotic myelopathy (CSM) is a potentially debilitating disorder

68 Cervical spondylotic myelopathy (CSM) is rising in the aging population.

69 measure of severity of cervical spondylotic myelopathy (CSM), which will be of use in determining th

70 irment in patients with cervical spondylotic myelopathy (CSM).

71 Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-PROTECT) trial, a multicenter, double-bl

72 ommon form of which is degenerative cervical myelopathy (DCM) - have provided important insights into

73 l, older patients with degenerative cervical myelopathy (DCM) are felt to have lower recovery potenti

74 Patients with degenerative cervical myelopathy (DCM) experience structural and functional br

75 Degenerative cervical myelopathy (DCM) is a common progressive disease of the

76 Degenerative cervical myelopathy (DCM) is a progressive chronic spinal cord in

77 site in patients with degenerative cervical myelopathy (DCM) using intravoxel incoherent motion (IVI

78 Degenerative cervical myelopathy (DCM), the leading cause of non-traumatic spi

79 represent outcomes of degenerative cervical myelopathy (DCM); however, it lacks consideration for ne

80 ventions for patients with acute and chronic myelopathies depend on preclinical animal models of inju

81 s, number of steps taken over this distance, myelopathy disability index (MDI), and Nurick scores.

82 Canine degenerative myelopathy (DM) is a fatal neurodegenerative disease pre

83 Canine degenerative myelopathy (DM) is a naturally occurring neurodegenerati

84 uffering from ALS-like disease, degenerative myelopathy (DM).

85 0 years with multilevel cervical spondylotic myelopathy enrolled at 15 large North American hospitals

86 2 women), we studied 14 MRIs during distinct myelopathy episodes and nine follow-up MRIs.

87 Bagel Sign was present in 13 of 14 myelopathy episodes whereas Motor Neuron pattern was obs

88 ons in patients with insidiously progressive myelopathy, especially with known cancer risk.

89 (AVMs) can lead to development of congestive myelopathy (Foix-Alajouanine syndrome).

90 erized by recurrent optic neuritis, cervical myelopathy from syringomyelia, paraparesis, amenorrhea-g

91 ignificant difference in TSC in the cervical myelopathy group (39 +/- 10 mM) relative to healthy cont

92 ymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is an inflammatory condition characteri

93 T-cell leukemia/lymphoma, HTLV-1-associated myelopathy (HAM), and other inflammatory disorders.

94 eukemia/lymphoma (ATL) and HTLV-I associated myelopathy (HAM).

95 us type 1 (HTLV-I) causing HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP)] and

96 implicated in the disease HTLV-1-associated myelopathy (HAM/TSP).

97 HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lymphotropic virus ty

98 opical spastic paraparesis/HTLV-1-associated myelopathy in about 5% of infected individuals.

99 This study showed that the natural course of myelopathy in CM-I-syringomyelia varies according to the

100 causes T-cell leukemia and HTLV-I-associated myelopathy in humans, has been determined by NMR methods

101 date its usability to detect microstructural myelopathy in NMDCCC patients.

102 important to investigate for other causes of myelopathy in these patients.

103 he central nervous system, HTLV-1-associated myelopathy, in ~0.3% to 4% of them, varying between regi

104 spinal cord thinning in chronic progressive myelopathies, including human T-lymphotropic virus 1 (HT

105 sociated neuroinflammatory diseases, notably myelopathy induced by retrovirus human T leukemia virus-

106 ell lymphotropic virus-I (HTLV-I)-associated myelopathy is a slowly progressive neurologic disease ch

107 INTRODUCTION: Myelopathy is considered the most common neurological co

108 Cervical spondylotic myelopathy is the most common cause of spinal cord dysfu

109 ding those on depression, dementia, vacuolar myelopathy, liver disease, and osteoarthritis.

110 al patients with DCM with moderate to severe myelopathy (mJOA scale score of 8-14) were randomized to

111 ephalopathy, chorea, brain stem dysfunction, myelopathy, mononeuritis multiplex, Guillain-Barre-like

112 long myelopathy (n = 9), both long and short myelopathy (n = 2) and short myelopathy (n = 2) was obse

113 long and short myelopathy (n = 2) and short myelopathy (n = 2) was observed.

114 Of the 13 MRIs with Bagel Sign long myelopathy (n = 9), both long and short myelopathy (n =

115 Cognitive impairment (N=38), myelopathy (N=23) and brainstem dysfunction (N=22) were

116 esis (HAM/TSP) is a progressive inflammatory myelopathy occurring in a subset of HTLV-1-infected indi

117 patients with: (1) longitudinally extensive myelopathy of other cause (n=66) and (2) myelitis in the

118 patients in whom serological evaluation for myelopathy of uncertain cause demonstrated collapsin res

119 ntrol patients had multiple sclerosis, other myelopathies, optic neuropathies, and miscellaneous diso

120 n (with breast cancer, p < 0.05) and to have myelopathy or stiff-man phenomena (p < 0.01).

121 egenerative disease called HTLV-I-associated myelopathy or tropical spastic paraparesis (HAM/TSP).

122 Felty's syndrome, cervical spine fusion for myelopathy, or total knee arthroplasty at hospitals in C

123 been observed in other forms of longitudinal myelopathy outside of BD, including neuromyelitis optica

124 opical spastic paraparesis-HTLV-1-associated myelopathy patients contain a Lys at position 88 in some

125 onclusion, using (23)Na-MRS, TSC in cervical myelopathy patients was successfully measured.

126 nts compared to patients with neuropathies & myelopathies, patients with myopathies and controls.

127 s, myoclonus, or both), cerebellar syndrome, myelopathy, peripheral neuropathy, cranial neuropathy, m

128 flammation-associated neurotoxicity, stroke, myelopathy, peripheral neuropathy, Guillain-Barre syndro

129 ation: multilevel decompression, preexisting myelopathy, pulmonary disease, cardiovascular disease, h

130 ncreased levels reflecting higher grading of myelopathy-related disability.

131 Degenerative cervical myelopathy represents the most common form of non-trauma

132 sing frequency): neuropathy, encephalopathy, myelopathy, stiff-man phenomena, and cerebellar syndrome

133 il December 2024 for significant progressive myelopathy that we termed 'obvious deterioration'.

134 ew neurologic conditions, such as stroke and myelopathy, that require ongoing neurologic surveillance

135 SOD1) is associated with canine degenerative myelopathy: the only naturally occurring large animal mo

136 iew of the different diseases that can cause myelopathy, their imaging manifestations, their differen

137 mphotropic virus type 1 (HTLV-1) -associated myelopathy/tropic spastic paraparesis is a demyelinating

138 Five of six HTLV-1-associated myelopathy/tropic spastic paraparesis patients carried a

139 leukemia and lymphoma and HTLV-1-associated myelopathy-tropical spastic paraparesis.

140 neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and ad

141 luding multiple sclerosis, HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) and ch

142 n T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and mu

143 ymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and mu

144 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) are kn

145 lymphotropic virus (HTLV) type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) based

146 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) exhibi

147 virus type I-associated (HTLV-I-associated) myelopathy/tropical spastic paraparesis (HAM/TSP) has be

148 ll leukemia virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a c

149 ymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a c

150 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a n

151 ymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a p

152 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an

153 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an

154 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an

155 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is ass

156 eukemia/lymphoma (ATL) and HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) is poo

157 leukemia/lymphoma (ATLL) or HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or dev

158 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) prolif

159 (+) Tregs in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) result

160 sult in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chr

161 ymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a dis

162 ukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a pro

163 us type I (HTLV-I) develop HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), an im

164 four of five patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), mono-

165 1 (HTLV-1) is the agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), obser

166 spinal cord, resulting in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), or ad

167 eurological disease termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

168 y, and disease severity of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

169 human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

170 T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

171 neurologic disease called HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

172 mphocytes of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

173 eurological disease termed HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

174 s (PBL) from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

175 T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

176 neuroinflammatory disease, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

177 T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

178 tral nervous system termed HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

179 the neurological disorder HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

180 ymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

181 T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

182 tory neurological disease (HTLV-I-associated myelopathy/tropical spastic paraparesis [HAM/TSP]) is su

183 adult T cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis after the initia

184 gically distinct diseases: HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T cell

185 T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis has been reporte

186 T cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis is a chronic pro

187 T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis patients using r

188 oviral load and determines HTLV-1-associated myelopathy/tropical spastic paraparesis risk.

189 iral load in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis suggest that HTL

190 ent in 12 individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis than in 29 asymp

191 Our analysis showed that HTLV-1-associated myelopathy/tropical spastic paraparesis was associated w

192 , the inflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis was associated w

193 l nervous system, HAM/TSP (HTLV-I-associated myelopathy/tropical spastic paraparesis), by reducing th

194 ic carrier or patient with HTLV-1-associated myelopathy/tropical spastic paraparesis), ongoing infect

195 ase human T cell leukemia virus-1-associated myelopathy/tropical spastic paraparesis, A6 also recogni

196 tis sicca in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, and HTLV-1-asso

197 tral nervous system (CNS), HTLV-I-associated myelopathy/tropical spastic paraparesis, characterized p

198 human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis, rheumatoid arth

199 adult T cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis.

200 adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis.

201 nd a neurological disease, HTLV-I-associated myelopathy/tropical spastic paraparesis.

202 T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

203 T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

204 T cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

205 tory conditions, including HTLV-1-associated myelopathy/tropical spastic paraparesis.

206 rological disease known as HTLV-I-associated myelopathy/tropical spastic paraparesis.

207 eukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis.

208 nt resemble those found in HTLV-I-associated myelopathy/tropical spastic paraparesis.

209 enerative disease known as HTLV-1-associated myelopathy/tropical spastic paraparesis.

210 cell leukemia/lymphoma and HTLV-1 associated-myelopathy/tropical spastic paraparesis.

211 adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis.

212 cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis.

213 netics are associated with HTLV-1-associated myelopathy/tropical spastic paraparesis?

214 eurological disease termed HTLV-1-associated myelopathy/tropical spastic paraperesis (HAM/TSP).

215 cal spastic paraparesis or HTLV-1-associated myelopathy (TSP/HAM).

216 opical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM).

217 cephalopathy (three), brainstem signs (two), myelopathy (two), parkinsonism (one)).

218 encephalopathy with/without seizures (two), myelopathy (two).

219 f whom 39 (83%) had hearing loss, ataxia, or myelopathy; type 2 (secondary) iSS included 17 patients

220 Among patients with cervical spondylotic myelopathy undergoing cervical spinal surgery, a ventral

221 g T cells in patients with HTLV-I-associated myelopathy was determined using MHC class I tetramers lo

222 Myelopathy was found in 21 patients.

223 wing criteria were included: (1) spondylotic myelopathy was suspected, (2) gadolinium enhancement was

224 ompression before evaluating other causes of myelopathy, which sometimes has multiple causes.

225 it to define "clinical symptoms of traumatic myelopathy with no radiographic or computed tomographic